It is more likely that the national healthcare systems eat up a large portion of the cost difference. It is not clear from the dataset however if this is purchase cost or end-user cost.

Prescription medication in Australia for example is heavily subsidised.

[–] Not_mikey@lemmy.dbzer0.com 11 points 3 months ago

It's more that the national health systems can negotiate prices for the whole country. If you can go to the pharma companies and say you're selling this drug for $100 or you're not selling the drug at all here then they're much more open to lowering the price.

Health insurance companies will also negotiate far below the sticker price listed above so they can go to their customers and say look this drug costs $900 but we got them down to only $200, aren't we a useful company and not a bunch of leeches? The problem is this makes it so the pharma companies have no incentive to lower sticker price as they'd only be missing out on the uninsured who aren't going to get it anyway, and the insurance companies like a high sticker price because it makes their "discounts" seem larger.

[–] turdas@suppo.fi 4 points 3 months ago

Finland isn't on that list, but the purchase cost here before any socialized healthcare rebates is ~110€ for a month's dose of Ozempic, which is in line with the other European countries, so presumably all the prices there are before any rebates.